SCHEMBL5532742

SCHEMBL5532742

Oc1nc(-c2ncco2)nc2ccsc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.36
ADORA1 P30542 11/20 0.36
SLC2A1 P11166 1/20 0.35
SPR P35270 1/20 0.34
PIK3CA P42336 3/20 0.33
MTOR P42345 2/20 0.33
MAPT P10636 1/20 0.33
HPGDS O60760 1/20 0.33
AXL P30530 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
PIK3C2B O00750 1/20 0.32
CCNE2 O96020 1/20 0.32
PRKACA P17612 1/20 0.32
PRKACG P22612 1/20 0.32
PRKACB P22694 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
KDR P35968 1/20 0.32
PIK3CB P42338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8146600 0.79 HTT (0.40) ADORA2AADORA1SLC2A1SPRMAPT
SCHEMBL14095091 0.72 PDE4A (0.52) ADORA2AADORA1PIK3CAMTORPIK3C2B
SCHEMBL577738 0.72 ADORA2A (0.53) ADORA2AADORA1SLC2A1MAPTNPC1
SCHEMBL14095203 0.71 PRKCI (0.39) ADORA2AADORA1PIK3CAMTORAXL
SCHEMBL14975194 0.70 PRKCI (0.39) ADORA2AADORA1SLC2A1SPRAXL
SCHEMBL7121620 0.70 PDE4A (0.55) ADORA2AADORA1PIK3CAMTORMAPT
SCHEMBL5532159 0.70 LATS1 (0.39) ADORA2AADORA1PIK3CAMTORMAPT
SCHEMBL14095195 0.69 ADORA2A (0.50) ADORA2AADORA1MAPTKMT2A
SCHEMBL5532728 0.69 ADORA2A (0.54) ADORA2AADORA1SLC2A1SPRPIK3CA
SCHEMBL13236422 0.69 ADORA2A (0.53) ADORA2AADORA1MAPTAXLMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211897-B2 Inhibitors of cathepsin B VIROBAY, INC. (US) 2012-07-03 US disclosed
US-8211897-B2 Inhibitors of cathepsin B VIROBAY, INC. (US) 2012-07-03 US disclosed
WO-2009100225-A1 INHIBITORS OF CATHEPSIN B VIROBAY, INC. (US) 2009-08-13 WO disclosed
US-20090203629-A1 INHIBITORS OF CATHEPSIN B VIROBAY, INC. (US) 2009-08-13 US disclosed
US-20090203629-A1 INHIBITORS OF CATHEPSIN B VIROBAY, INC. (US) 2009-08-13 US disclosed
US-20080161254-A1 HCV INHIBITORS VIROBAY, INC. (US) 2008-07-03 US disclosed
US-20070249637-A1 Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same COLLINS MICHAEL R 2007-10-25 US disclosed
US-20070249637-A1 Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same COLLINS MICHAEL R 2007-10-25 US disclosed
US-20070249637-A1 Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same COLLINS MICHAEL R 2007-10-25 US disclosed
EP-1805187-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME Pfizer, Inc. (US) 2007-07-11 EP disclosed
WO-2006043145-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161254-A1 HCV INHIBITORS HAVCR2, ZC3HAV1, EIF2AK2 ADORA2A 3228/4885ADORA1 2845/4885SLC2A1 3916/4885
US-20070249637-A1 Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same SERPINB1, CTSC, CTSV ADORA2A 4505/4885ADORA1 3990/4885SLC2A1 3816/4885
US-20090203629-A1 INHIBITORS OF CATHEPSIN B CTSB, CSTB, CTSF ADORA2A 2613/4885ADORA1 1664/4885SLC2A1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.